PolyPid Ltd
Company Profile
Business description
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
Contact
18 Hasivim Street
Petach Tikva495376
ISRT: +972 747195700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
75
Stocks News & Analysis
stocks
Ask the Analyst: Why are ASX gold miners overvalued despite a near record gold price?
stocks
Chart of the Week: Looking past the oil shock to find consumer opportunities
stocks
ASX data center player sells US assets to bolster balance sheet
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,107.00 | 36.90 | 0.41% |
| CAC 40 | 8,287.11 | 12.31 | -0.15% |
| DAX 40 | 24,870.85 | 47.84 | -0.19% |
| Dow JONES (US) | 49,910.59 | 612.34 | 1.24% |
| FTSE 100 | 10,364.28 | 74.38 | -0.71% |
| HKSE | 26,626.28 | 412.50 | 1.57% |
| NASDAQ | 25,838.94 | 512.82 | 2.02% |
| Nikkei 225 | 62,833.84 | 3,320.72 | 5.58% |
| NZX 50 Index | 13,270.61 | 125.42 | 0.95% |
| S&P 500 | 7,365.12 | 105.90 | 1.46% |
| S&P/ASX 200 | 8,878.10 | 32.70 | 0.37% |
| SSE Composite Index | 4,180.09 | 19.92 | 0.48% |